Clene to Present at the Canaccord 45th Annual Growth Conference

Core Insights - Clene Inc. is a late clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases such as ALS and MS [1][3] - The company will present at the Canaccord 45th Annual Growth Conference and host one-on-one investor meetings [1][2] Company Overview - Clene Inc. and its subsidiary Clene Nanomedicine Inc. aim to improve mitochondrial health and protect neuronal function [3] - The investigational therapy CNM-Au8 targets mitochondrial function and the NAD pathway, reducing oxidative stress to enhance the survival and function of central nervous system cells [3] - Clene is headquartered in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland [3]